{"id":75577,"date":"2026-08-20T12:13:46","date_gmt":"2026-08-20T04:13:46","guid":{"rendered":"https:\/\/flcube.com\/?p=75577"},"modified":"2026-08-20T12:13:47","modified_gmt":"2026-08-20T04:13:47","slug":"abbisko-wins-nmpa-ind-clearance-for-pan-kras-inhibitor-absk211-in-advanced-solid-tumors-following-fda-green-light","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75577","title":{"rendered":"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Abbisko Therapeutics Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2256:HKG\">HKG: 2256<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has cleared the <strong>Investigational New Drug (IND) application for ABSK211<\/strong> in patients with <strong>advanced solid tumors harboring KRAS alterations<\/strong>. The clearance follows <strong>U.S. FDA IND clearance<\/strong> for the same program on <strong>7 Jul 2026<\/strong>, enabling global clinical development of the oral pan\u2011KRAS inhibitor.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestones\" class=\"wp-block-heading\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Abbisko Therapeutics Co., Ltd. (HKG: 2256)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ABSK211 (oral small\u2011molecule pan\u2011KRAS inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors harboring KRAS alterations<\/td><\/tr><tr><td><strong>NMPA IND Clearance<\/strong><\/td><td>Announced 19 Aug 2026<\/td><\/tr><tr><td><strong>FDA IND Clearance<\/strong><\/td><td>7 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Global clinical development of ABSK211<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Oral, highly potent small\u2011molecule <strong>pan\u2011KRAS inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Coverage:<\/strong> Broad\u2011spectrum activity against multiple KRAS alterations, including <strong>KRAS G12D, G12C, G12S, G12V, G13D<\/strong>, and <strong>KRAS wild\u2011type amplification<\/strong><\/li>\n\n\n\n<li><strong>Preclinical Evidence:<\/strong> Promising <strong>antitumor activity<\/strong> and favorable <strong>selectivity<\/strong>, both as <strong>monotherapy<\/strong> and in <strong>combination settings<\/strong><\/li>\n\n\n\n<li><strong>Positioning:<\/strong> Potential new therapeutic option for patients with solid tumors harboring KRAS alterations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Regulatory Footprint:<\/strong> Back\u2011to\u2011back FDA and NMPA IND clearances within six weeks enable synchronized global clinical development of ABSK211 \u2014 a key differentiator for Chinese biotechs seeking worldwide reach.<\/li>\n\n\n\n<li><strong>Broad KRAS Coverage:<\/strong> Targeting multiple KRAS mutations \u2014 including the notoriously difficult <strong>G12D<\/strong> \u2014 plus wild\u2011type amplification positions ABSK211 as a potentially differentiated asset in one of oncology&#8217;s most competitive and underserved target spaces.<\/li>\n\n\n\n<li><strong>Combination Flexibility:<\/strong> Preclinical activity in combination settings suggests future development optionality alongside standard\u2011of\u2011care regimens in KRAS\u2011driven solid tumors.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the clinical development, efficacy, and regulatory pathway of ABSK211. Actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[186,62,921],"class_list":["post-75577","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-clinical-trial-approval-initiation","tag-hkg-2256"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China&#039;s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan\u2011KRAS inhibitor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75577\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light\" \/>\n<meta property=\"og:description\" content=\"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China&#039;s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan\u2011KRAS inhibitor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75577\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-20T04:13:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T04:13:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75577#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75577\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light\",\"datePublished\":\"2026-08-20T04:13:46+00:00\",\"dateModified\":\"2026-08-20T04:13:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75577\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbisko Therapeutics\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2256\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75577#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75577\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75577\",\"name\":\"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-20T04:13:46+00:00\",\"dateModified\":\"2026-08-20T04:13:47+00:00\",\"description\":\"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan\u2011KRAS inhibitor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75577#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75577\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75577#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light - Insight, China&#039;s Pharmaceutical Industry","description":"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan\u2011KRAS inhibitor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75577","og_locale":"en_US","og_type":"article","og_title":"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light","og_description":"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan\u2011KRAS inhibitor.","og_url":"https:\/\/flcube.com\/?p=75577","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-20T04:13:46+00:00","article_modified_time":"2026-08-20T04:13:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75577#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75577"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light","datePublished":"2026-08-20T04:13:46+00:00","dateModified":"2026-08-20T04:13:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75577"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbisko Therapeutics","Clinical trial approval \/ initiation","HKG: 2256"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75577#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75577","url":"https:\/\/flcube.com\/?p=75577","name":"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-20T04:13:46+00:00","dateModified":"2026-08-20T04:13:47+00:00","description":"Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that China's National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for ABSK211 in patients with advanced solid tumors harboring KRAS alterations. The clearance follows U.S. FDA IND clearance for the same program on 7 Jul 2026, enabling global clinical development of the oral pan\u2011KRAS inhibitor.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75577#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75577"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75577#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbisko Wins NMPA IND Clearance for Pan\u2011KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75577"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75577\/revisions"}],"predecessor-version":[{"id":75578,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75577\/revisions\/75578"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}